Home » Stocks » Endo International

Endo International PLC (ENDP)

Stock Price: $3.62 USD 0.14 (4.02%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
After-hours: $3.61 -0.01 (-0.28%) Aug 3, 7:47 PM

Stock Price Chart

Key Info

Market Cap 831.53M
Revenue (ttm) 3.01B
Net Income (ttm) -274.13M
Shares Out 229.70M
EPS (ttm) -1.21
PE Ratio n/a
Forward PE 1.74
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 3, 2020
Last Price $3.62
Previous Close $3.48
Change ($) 0.14
Change (%) 4.02%
Day's Open 3.48
Day's Range 3.43 - 3.64
Day's Volume 3,403,890
52-Week Range 1.97 - 7.10

More Stats

Market Cap 831.53M
Enterprise Value 7.54B
Earnings Date (est) Aug 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 229.70M
Float 211.15M
EPS (basic) -1.22
EPS (diluted) -1.21
FCF / Share 0.81
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 22.02%
Payout Ratio n/a
Shares Short 26.50M
Short Ratio 4.23
Short % of Float 17.01%
Beta 1.54
PE Ratio n/a
Forward PE 1.74
P/FCF Ratio 4.54
PS Ratio 0.28
PB Ratio n/a
Revenue 3.01B
Operating Income 216.99M
Net Income -274.13M
Free Cash Flow 183.09M
Net Cash -6.71B
Net Cash / Share -29.23
Gross Margin 44.81%
Operating Margin 7.20%
Profit Margin -9.10%
FCF Margin 6.07%
ROA 4.47%
ROE n/a
ROIC 1.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (15)

Buy 3
Overweight 0
Hold 9
Underweight 0
Sell 3

Analyst Consensus: Hold

Price Target

(48.07% upside)
Current: $3.62
Target: 5.36
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-1.11%-15.04%-13.5%22.69%37.3%12.05%-24.54%11.52%47.12%-
Gross Profit1,3451,3151,2401,3751,1931,1491,2381,6801,5771,211
Operating Income74.00-417-943-3,471-997359570-540466467
Net Income-423-1,031-2,035-3,347-1,495-721-685-740188259
Shares Outstanding226224223223197147113116117116
Earnings Per Share-1.87-4.61-9.12-15.03-7.59-4.60-5.72-6.401.552.20
EPS Growth---------29.55%-
Operating Cash Flow98.05267554528119338299734702454
Capital Expenditures-63.85-83.40-126-139-81.77-80.25-94.63-98.39-57.76-19.54
Free Cash Flow34.2018442838936.73258204635644434
Cash & Equivalents1,7021,4541,3077998589371,297530548466
Total Debt8,4538,2588,2768,2738,5804,2573,7393,1673,5131,071
Net Cash / Debt-6,751-6,804-6,969-7,473-7,723-3,319-2,442-2,637-2,965-605
Book Value-867-4984852,7025,9682,3755261,0731,9781,742
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Endo International PLC
Country Ireland
Employees 3,172
CEO Blaise Coleman

Stock Information

Ticker Symbol ENDP
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: ENDP
IPO Date September 25, 1996


Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; TESTOPEL for TRT in conditions associated with a deficiency or absence of endogenous testosterone; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; VOLTAREN gel for the relief of joint pain of osteoarthritis; LIDODERM for the relief of pain; TESTOPEL, an implantable pellet indicated for TRT in conditions; EDEX to treat erectile dysfunction; and LIDODERM a topical patch product containing lidocaine. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays; and products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.